4//SEC Filing
Rhodes Jason P 4
Accession 0000950170-25-081356
CIK 0001818794other
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 9:39 PM ET
Size
5.8 KB
Accession
0000950170-25-081356
Insider Transaction Report
Form 4
Rhodes Jason P
Director
Transactions
- Award
Stock option (right to buy)
2025-05-30+35,000→ 35,000 totalExercise: $11.96Exp: 2035-05-29→ Common Stock (35,000 underlying)
Footnotes (2)
- [F1]This option was granted on May 30, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 30, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.
- [F2]The Reporting Person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
Documents
Issuer
Dyne Therapeutics, Inc.
CIK 0001818794
Entity typeother
Related Parties
1- filerCIK 0001577014
Filing Metadata
- Form type
- 4
- Filed
- Jun 2, 8:00 PM ET
- Accepted
- Jun 3, 9:39 PM ET
- Size
- 5.8 KB